SMi Group's 7th annual Advances in Cell Based Assays conference is back this November in London

1. SMi present the 7th annual conference...
11th - 12th
NOV
2014Marriott Regents Park Hotel, London, UK
Advances in
Cell Based Assays
@SMIpharm
www.cellbasedassay.co.uk
Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
CONFERENCE CHAIRS:
• Steve Ludbrook,
Group Leader,
Biological Sciences UK, RD Platform
Technology & Science, GSK
• Dr Beverley Isherwood,
Team Leader High Content Biology,
Innovative Medicines,
AstraZeneca R&D
KEY SPEAKERS INCLUDE:
• Dr Lesley Jenkinson, Scientist 1, Medimmune
• Dr Farnaz Fallah-Arani, Group Leader, Pharmacology, UCB
• Neil Carragher, PhD, Principal Investigator Drug Discovery, Edinburgh
Cancer Research UK Centre, Institute of Genetics and Molecular
Medicine, University of Edinburgh
• Davide Danovi, Director, HipSci Cell Phenotyping, Guy's Hospital
• Niclas Nilsson, Head of Section, Lead Discovery, LEO Pharma, Denmark
• Dr Christa Burger, Principal Scientist, Cellular Pharmacology, Merck Serono
• Dr Marianne Uteng, PhD, Head of Cellular Models & HCB Laboratory,
Discovery and Investigative Safety (DIS), Novartis
• Anker Jon Hansen, Principal Scientist, Novo Nordisk
• Daniel Nolan, Director of Research, Angiocrine Bioscience
• Jonathan Rock, Senior Sales Specialist-Emerging Technologies, Sigma
Aldrich
Explore the latest developments to extend
your market dominance
REGISTER BY 18TH JULY AND RECEIVE A £300 DISCOUNT
REGISTER BY 30TH SEPTEMBER AND RECEIVE A £100 DISCOUNT
PLUS TWO INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOPS
Thursday 13th November 2014, Marriott Regents Park Hotel, London, UK
A: Unleashing the power of advanced
cell-based assays to fuel open innovation
Workshop Leader: Niclas Nilsson, Open Innovation Manager,
Early Pipeline and Innovation Centre, LEO Pharma, Denmark
8.30am – 12.30pm
B: A critical evaluation of cell-based assays
in pre-clinical drug discovery
Workshop Leader: Sheraz Gul, Vice President and Head of
Biology, European ScreeningPort GmbH
1.30pm – 5.30pm
BENEFITS OF ATTENDING:
• New for 2014 - cell based assays and regulatory guidelines –
what you need to know!
• New for 2014 - Peep into the future with a look at next
generation cell based assays
• Discover new and novel approaches for the application of
3D cell cultures
• Hear the latest on stem cell developments including gene
editing technologies
• Hear from over 8 pharma plus academics who will share their
expert knowledge in cell based assays!
Sponsored by

2. Register online at: www.cellbasedassay.co.uk • Alternatively fax y
Advances in Cell Based Assays Conference
Day One | Tuesday 11th November 2014
8.30 Registration & Coffee
9.00 Chairman's Opening Remarks
Steve Ludbrook, Group Leader, Biological Sciences UK, RD
Platform Technology & Science, GSK
REGULATORY UPDATE AND DRUG DEVELOPMENTS
9.10 Cell based assays in biologics drug discovery
•Cell based assays are the assays of choice for identifying
functionally active therapeutics with the right epitope and
mechanism of action
•The use of cell based assays for high throughput testing of
un-purified biologics samples is challenging due to sample
tolerance and assay sensitivity
•Recent advances in high throughput sample expression
techniques have opened up new possibilities for primary HTS
within the biologics industry
•The application of cell based assays in biologics discovery, and
the use of new higher throughput sample expression
techniques for cell-based primary HTS will be described
Lesley Jenkinson, Scientist 1, Antibody Discovery and Protein
Engineering, Medimmune
9.50 Challenges of bioassay methods development and validation
with reference to cell based assays & regulatory guidelines in
drug development
•Cell based assays are highly variable and pose numerous
challenges in drug development and technology transfer from
analytical laboratories to quality control
•Discuss strategies to development and validation
•Review current regulatory thinking (EMA and US-FDA)
Dr Niranjan Kumar, Ph.D, EMBA, President, ABS Inc. USA
10.30 Morning Coffee
10.50 Using immunological human in vitro assays and their
corresponding in vivo model systems to determine target
specific mode of action of small and large molecules
•Specific immunological human and mouse in vitro assay and
their corresponding in vivo models will be discussed
•How can these models be used to determine functionality and
potency of different molecules and how translatable are these
findings into the clinic
Dr Farnaz Fallah-Arani, Group Leader, Pharmacology, UCB
11.30 The many assay approaches for assessing mitochondrial
toxicity, and their strategic use in drug development
•Indirect, direct and mechanistic assays
•Integrated approaches
•When, what and how to assess
•Case studies
Dr Marianne Uteng, PhD, Head of Cellular Models & HCB
Laboratory, Discovery and Investigative Safety (DIS), Novartis
12.10 Networking Lunch
1.10 Use of the single cell gel electrophoresis (comet) assay in drug
development
Professor John A Hartley, Professor of Cancer Studies, Co-Lead,
UCL Experimental Cancer Medicine Centre, UCL and Founder
Scientist and Director of Pre-Clinical Development, Spirogen Ltd
PHENOTYPIC SCREENING USING CELL BASED ASSAYS
1.50 Aligning Drug Discovery Critical Paths to Clinical Translation with
Human Disease Relevant Cell based assays
•Current focus on translationally-aligned drug discovery
approaches
•Potential to accelerate the uptake of primary cell screening
systems
•Increased usage of phenotypic assays and primary screening
activities for hit identification
Steve Ludbrook, Group Leader, Biological Sciences UK, RD
Platform Technology & Science, GSK
2.30 Next Generation Target Identification and Screening
Technologies.
•An overview of High Content Screening technologies and their
applications including:-
- Genome Editing Tools (ZFN, CRISPR)
- Custom Engineered cell lines and disease models
- Protein-Protein interaction detection (Duolink)
- RNAi and miRNA technologies.
Jonathan Rock, Senior Sales Specialist-Emerging Technologies,
Sigma Aldrich
3.10 Afternoon Tea
3.40 Development of phenotypic and disease-relevant in vitro assays
for open innovation
•Changing business need for classic in vitro assays
•Gearing up early in vitro drug research for global innovation
•Practical hurdles when developing advanced cell-based
assays for open innovation
Niclas Nilsson, Head of Section, Lead Discovery, LEO Pharma,
Denmark
LABEL FREE
4.20 Reviewing the value of electrical impedance sensing for label-
free detection of cellular pharmacology
•Analysing how this method is ideal for measuring cell adhesion
and growth
•Understanding how cell death can be measured on-line
- and how cell activation can be monitored
•Discussing endothelial/epithelial barrier function
Anker Jon Hansen, Scientific Director,Cellular Pharmacology,
Novo Nordisk
5.00 How easy or not is it to use adult stem cells
in therapeutic applications, in vitro and in
vivo paradigm?
•Discussing how these "adult stem cells" have been developed
using virus particles
•For differentiating into specific tissues/organs what are the
potential road blocks and or barriers with reference to
regulatory, safety issues?
•Analysing the challenges and safety concerns of future stem cell
and cell based assay technologies and how to overcome them
Dr. Niranjan Kumar, Ph.D, EMBA, President, ABS Inc. USA
5.40 Chairman's Closing Remarks and Close of Day One
SPONSORSHIP AND
EXHIBITION OPPORTUNITIES
SMi offer sponsorship, exhibition, advertising
and branding packages, uniquely tailored to
complement your company’s marketing
strategy. Prime networking opportunities exist
to entertain, enhance and expand your client
base within the context of an independent
discussion specific to your industry. Should
you wish to join the increasing number of
companies benefiting from sponsoring our
conferences please call:
Alia Malick on +44 (0) 20 7827 6168
or email: amalick@smi-online.co.uk
PANEL
DISCUSSION
Sponsored by
Sigma-Aldrich is a leading Life Science and High Technology company. Our
biochemical and organic chemical products and kits are used in scientific and
genomic research, biotechnology, pharmaceutical development, the diagnosis of
disease and as key components in pharmaceutical and other high technology
manufacturing. www.sigma-aldrich.com

3. Supported by
your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711
Day Two | Wednesday 12th November 2014
8.30 Registration & Coffee
9.00 Chairman's Opening Remarks
Dr Beverley Isherwood, Team Leader High Content Biology,
Innovative Medicines, AstraZeneca R&D
STEM CELLS
9.10 Gene editing technologies in the context of cell based
assays
•Exploiting gene-editing in human cell lines to provide
novel, isogenic assays
•What technologies are available
•How are these impacting the industry
Ashley Barnes, Group Leader, Biological Sciences, GSK
9.50 High content analysis using stem cells for disease modelling
and drug discovery
•Current challenges in the use of stem cells in phenotype
screening
•Defining boundaries between health and disease at a
single cell level
•The human induced pluripotent stem cell initiative cell
phenotyping strategy
Davide Danovi, Director, HipSci Cell Phenotyping, Centre for
Stem Cells and Regenerative Medicine, King's College
London
10.30 Morning Coffee
10.50 VeraVec endothelial cells recreate the vascular stem cell in
vitro for stem cell expansion and drug discovery
•The vascular stem cell niche is capable of expanding stem
cells in vitro while maintaining potency and engraftability
•The VeraVec platform has applicability for various stem
cells; UCB, iPSC, hESC, neural, malignant, etc
•VeraVec ECs are amenable to 3D and co-culture assays for
screening purposes
•Recent work has demonstrated the chemoresistant niche
within cancer involves the vasculature, which is also
modeled by VeraVecs
Dr. Daniel Nolan, Director of Research, Angiocrine Bioscience
APPLICATION OF 3D CULTURES
11.30 Introducing 3D cell culture in oncology research
•The first lab-grown epidermis with a functional barrier is an
efficient and cost-effective alternative in vitro model for testing
drugs and cosmetics
•Use of human embryonic stem cells (hSEC) or induced
pluripotent stem cells (iPSC)-derived keratinocytes allow an
unlimited number of genetically identical HEE units
•Easy to be scaled up and adapted to cGMP requirements
•Model to study how the skin barrier develops normally, how the
barrier is impaired in different diseases and how we can
stimulate its repair and recovery
Dr Dusko Ilic MD PhD, Reader in Stem Cell Science, Division of
Women's Health, King's College London
12.10 Networking Lunch
1.10 3D cell culture developments in technology to improve in vitro
analyses
•Developments in vitro cell based assay application of 3d
culture with enhanced cell structure and function
•Understanding why 3D cell culture technologies are essential
for pharmaceutical research
•Reviewing the newest developments in the key areas of 3D cell
culture technologies
- advanced 3D cell culture models for efficacy and safety studies
- enabling technologies to create and analyze biological reactions
- successful implementation in compound de-risking
•Newest developments in the key areas of 3D cell culture
technologies
Dr, Magnus Ingelman-Sundberg, Professor, Section Head, Vice
Chairman, Section of Pharmacogenetics, Department of
Physiology and Pharmacology, Karolinska Institutet
NEXT GENERATION CELL BASED ASSAYS
1.50 Next generation phenotypic screening
•Evaluating how to implement a more holistic approach that
incorporates phenotypic approach and molecular or
target-based discovery modes
•Reviewing companies that use phenotypic drug discovery,
what are the findings?
•Examining the challenges of phenotypic screening.
•Future perspectives – 3D, 2D, tissues, where are we going?
Neil Carragher, PhD, Principal Investigator Drug Discovery,
Edinburgh Cancer Research UK Centre, Institute of Genetics
and Molecular Medicine, University of Edinburgh
2.30 Afternoon Tea
2.50 Advancing drug discovery success through phenotypic
profiling
•Strategies for driving impact across the value chain
•Practices and technological innovations in HCA, cell
biology and data analytics as success factors to
application
•Case scenarios on the utilisation of a phenotypic
compound profiling platform at AstraZeneca
Dr Beverley Isherwood, Team Leader High Content Biology,
Innovative Medicines, AstraZeneca R&D
3.30 Reviewing the steps to more physiological cell models
•Discussing high content screening
•Primary cells
•Introducing 3D models
Dr. Christa Burger, Principal Scientist, Cellular Pharmacology,
Merck Serono
4.10 Chairman’s Closing Remarks and Close of Day Two
Official Media Partner
Interested in promoting your services to this market? Contact Teri Arri, SMi Marketing on +44 (0) 207 827 6162 or email tarri@smi-online.co.uk

4. HALF-DAY POST-CONFERENCE AM WORKSHOP
Thursday 13th November, 2014
8.30am – 12.30pm
Marriott Regents Park Hotel, London, UK
A: Unleashing the power of advanced
cell-based assays to fuel open innovation
Workshop Leader:
Niclas Nilsson, Open Innovation Manager, Early
Pipeline and Innovation Centre, LEO Pharma A/S
Overview of Workshop:
The workshop will touch upon the combination of cell-based,
phenotypic assay and open innovation - how internal in vitro
assets can be used better to drive drug research innovation
and create external collaboration opportunities. The focus of
the workshop is how to develop and use advanced cell-
based assays in open innovation platforms.
Why you should attend:
• Get introduced to the concept of open assay access
to fuel open innovation
• Understand critical hurdles and how to address them
• Hear about what cell-based assays should be able to
deliver as an open innovation asset
• Discuss key parameters to attract partners to your asset,
or how your asset could provide value for someone
elsegeneric.
Programme:
8.30 Registration and coffee
9.00 Opening remarks
9.10 Session 1. Overview of existing open innovation in
drug research
• What is Open Innovation
• Pharma examples
• Intentions – what we want to achieve and how
to do it
9.50 Session 2. Open access to advanced-cell based
assays
• Examples of existing assays
• What to consider when developing the assay
platform
• Disease-relevant phenotypic assays
10.30 Coffee break
11.00 Session 3. Overcoming practical issues during
implementation
• Potential legal issues
• Material transfer agreement
• Compounds management
• Joining internal and external assay process flows
• Data and results
11.40 Session 4. Spinning in the outcome – how to handle
positive results and generate business value
• Follow-up studies
• Overcoming “not invented here” mentality
• Fueling the pipeline
12.20 Closing remarks
12.30 End of workshop
About the workshop host:
Niclas Nilsson MSc PhD, has a 10 years’
experience in pharmaceutical in vitro assay
development with focus on advanced cell-
based assays, including phenotypic assay to
forward drug research. Recently Niclas has
focused on creating collaborative
opportunities using cell-based assays as an open innovation
platform to meet the growing need for boosting R&D
innovation and external collaboration.
About Leo Pharma:
Founded in 1908, LEO Pharma is an
independent, research-based pharmaceutical
company which is fully foundation owned.
LEO Pharma develops, manufactures and
markets pharmaceutical drugs to
dermatologic and thrombotic patients in more than 100
countries globally. LEO Pharma has its own sales forces in 61
countries and employs around 4,800 employees worldwide.
The company is headquartered in Denmark and is wholly
owned by the LEO Foundation.

5. HALF-DAY POST-CONFERENCE PM WORKSHOP
Thursday 13th November 2014
1.30pm - 6.00pm
Marriott Regents Park Hotel, London, UK
A critical evaluation of cell-based assays in
pre-clinical drug discovery
Workshop Leader:
Sheraz Gul, Vice President and Head of Biology,
EuropeanScreening Port GmbH
Overview of Workshop:
A typical small molecule drug discovery project will aim to
identify chemical starting points that modify the functions of
genes, cells, or biochemical pathways. In some but not all
instances, these functions may be linked to disease processes,
and an opportunity will exist to further develop the chemical
starting points into novel therapeutic agents. We have witnessed
a resurgence of cell-based assays in pre-clinical drug discovery
and this workshop will critically evaluate both target-based
biochemical assays and cell-based assays, with the ultimate aim
of these to reduce compound attrition and the enable the
successful translation of compound activities in vivo.
Why you should attend:
The workshop is designed for scientists at all levels from core
facilities, contract research organisations within academic and
industrial research organisations engaged in early stage drug
discovery who have an interest in the development, validation
and utilisation of cell-based assays for screening against small
molecule libraries. It is anticipated that the workshop will extend
the expertise of the participants.
Programme:
1.30 Registration and coffee
2.00 Opening remarks
2.15 Session1:Drugdiscovery,chemicalbiologyandprobe
discovery
• A historical overview of drug discovery, chemical
biology and probe discovery including case studies
3.00 Session 2: Target-based biochemical assays in pre-
clinical drug discovery
• An overview of target-based biochemical assays that
are employed in pre-clinical drug discovery
3.45 Coffee break
4.15 Session 3: Cell-based assays in pre-clinical drug discovery
• An overview of cell-based assays that are employed
in pre-clinical drug discovery
5.00 Session 4: Integrating your research program, design of
project critical paths which integrate in-vitro, in-silico
and in-vivo elements
• Construction of critical pathways for pre-clinical drug
discovery projects, appreciate that a variety of tools
are required to ensure project progression
5.45 Closing remarks
6.00 End of workshop
About the workshop host:
Sheraz Gul has been the Vice President and Head of
BiologyatEuropeanScreeningPortGmbH,Hamburg,
Germany since 2008 where he manages the assay
development and screening of academic drug
targets. Prior to this, he worked for GlaxoSmithKline for
7 years where he developed biochemical and
cellular assays for High Throughput Screening as well as Hit
characterization.HehasaPhDand5yearspost-doctoralresearch
experience all from the University of London. He has co-authored
numerouspapers,bookchaptersandtheEnzymeAssays:Essential
Data Handbook. In addition, he has been appointed to the
editorial boards of the European Pharmaceutical Review and
International Drug Discovery, is the Scientific Editor of Drug Target
Review, a scientific co-founder of Transcriptogen Ltd and is an
advisor to a number of biotech companies.
He is involved in various EU-FP7, IMI and COST Action projects
where he leads various work-packages and is involved in
translating basic research to drug discovery.
In addition, he co-ordinates the 3 day practical workshops run at
the European ScreeningPort GmbH in conjunction with the
European Pharmaceutical Review and is the joint co-ordinator
of the EMBL Master Course-Chemical Biology Screening.
About The European ScreeningPort:
The European ScreeningPort
GmbH (ESP) is a Public
Private Partnership which
receives project-based
funding from national governments, industry and academic
institutions. ESP offers industry scale small molecule Hit-finding
capability to academic organisations within Europe and
collaborates closely with the pharmaceutical industry in multiple
projects.Approximately50%oftheESPHitfindingprojectsinvolve
cell-basedassayreadouts.TheESPprovidesscreeningservicesto
multiple academic partners from across the globe.

6. FAX your booking form to +44 (0) 870 9090 712
PHONE on +44 (0) 870 9090 711
POST your booking form to: Events Team, SMi Group Ltd, 2nd Floor
South, Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, UK
ADVANCES IN CELL BASED ASSAYS CONFERENCE
Conference: Tuesday 11th & Wednesday 12th November 2014, Marriott Hotel Regents Park, London, UK Workshops: Thursday 13th November 2014, London
4 WAYS TO REGISTER
www.cellbasedassay.co.uk
If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email events@smi-online.co.uk
Payment: If payment is not made at the time of booking, then an invoice will be issued and must be
paid immediately and prior to the start of the event. If payment has not been received then credit
card details will be requested and payment taken before entry to the event. Bookings within 7 days
ofeventrequirepaymentonbooking.AccesstotheDocumentPortalwillnotbegivenuntilpayment
has been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another
delegate to take your place at any time prior to the start of the event. Two or more delegates may
not ‘share’ a place at an event. Please make separate bookings for each delegate.
Cancellation: If you wish to cancel your attendance at an event and you are unable to send a
substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing
that cancellation is made in writing and received at least 28 days prior to the start of the event.
Regretfully cancellation after this time cannot be accepted. We will however provide the
conferences documentation via the Document Portal to any delegate who has paid but is unable
to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to
provide documentation in these circumstances. We cannot accept cancellations of orders placed
for Documentation or the Document Portal as these are reproduced specifically to order. If we have
to cancel the event for any reason, then we will make a full refund immediately, but disclaim any
further liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing,
venue or date of the event compared to the advertised programme.
Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection
Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other
products and services. Unless you tick here □ we may also share your data with third parties offering
complementary products or services. If you have any queries or want to update any of the data that
we hold then please contact our Database Manager databasemanager@smi-online.co.uk or visit
our website www.smi-online.co.uk/updates quoting the URN as detailed above your address on the
attached letter.
Unique Reference Number
Our Reference LVP-122
Terms and Conditions of Booking
DELEGATE DETAILS
Please complete fully and clearly in capital letters. Please photocopy for additional delegates.
Title: Forename:
Surname:
Job Title:
Department/Division:
Company/Organisation:
Email:
Company VAT Number:
Address:
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Mobile:
Switchboard:
Signature: Date:
I agree to be bound by SMi's Terms and Conditions of Booking.
ACCOUNTS DEPT
Title: Forename:
Surname:
Email:
Address (if different from above):
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
VENUE Marriott Hotel Regents Park, 128 King Henry's Road, London, NW3 3ST
□ Please contact me to book my hotel
Alternatively call us on +44 (0) 870 9090 711,
email: hotels@smi-online.co.uk or fax +44 (0) 870 9090 712
□ Book by 18th July to receive £300 off the conference price
□ Book by 30th September to receive £100 off the conference price
EARLY BIRD
DISCOUNT
Payment must be made to SMi Group Ltd, and received before the event, by one of
the following methods quoting reference P-122 and the delegate’s name. Bookings
made within 7 days of the event require payment on booking, methods of payment
are below. Please indicate method of payment:
□ UK BACS Sort Code 300009, Account 00936418
□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOYDGB21013, Account 00936418
IBAN GB48 LOYD 3000 0900 9364 18
□ Cheque We can only accept Sterling cheques drawn on a UK bank.
□ Credit Card □ Visa □ MasterCard □ American Express
All credit card payments will be subject to standard credit card charges.
Card No: □□□□ □□□□ □□□□ □□□□
Valid From □□/□□ Expiry Date □□/□□
CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
Cardholder’s Name:
Signature: Date:
I agree to be bound by SMi's Terms and Conditions of Booking.
Card Billing Address (If different from above):
LIVE STREAMING/ON DEMAND/ DOCUMENTATION
Unable to travel, but would like to watch the conference live, ask questions,
participate as if you were in the room. Price Total
□ Live Streaming £999.00 + VAT (UK) £1198.80
□ On demand £599.00 + VAT (UK) £718.80
(available 24 hours after the event)
□ Access to the conference documentation
on the Document Portal £499.00 + VAT £598.80
□ The Conference Presentations - paper copy £499.00 - £499.00
(or only £300 if ordered with the Document Portal)
PAYMENT
VAT
VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on live
Streaming, on Demand, Document portal and literature distribution for all UK customers and
for those EU Customers not supplying a registration number for their own country here.
______________________________________________________________________________________________
CONFERENCE PRICES
I would like to attend: (Please tick as appropriate) Fee Total
□ Conference and 2 Workshops £2697.00 +VAT £3236.40
□ Conference and 1 Workshop £2098.00 +VAT £2517.60
□ Conference only £1499.00 +VAT £1798.80
□ 2 Workshops only £1198.00 +VAT £1437.60
□ 1 Workshop only £599.00 +VAT £718.80
PROMOTIONAL LITERATURE DISTRIBUTION
□ Distribution of your company’s promotional
literature to all conference attendees £999.00 + VAT £1198.80
The conference fee includes refreshments, lunch, conference papers, and access to the
Document Portal. Presentations that are available for download will be subject to
distribution rights by speakers. Please note that some presentations may not be available
for download. Access information for the document portal will be sent to the e-mail
address provided during registration. Details are sent within 24 hours post conference.